RxDoctor Payments Data

David Knoll, MD

Internal Medicine · Maryville, TNNPI 1306815253

Payments from drug & device makers

$1,076in general payments, 2019–2025

Across 41 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$293
  • Pfizer$159
  • La Jolla Pharmaceutical Company$133
  • Axonics, Inc.$129
  • AbbVie$91
  • Novo Nordisk$64
  • plus $207 from 8 others

What the payments were for

  • Food & beverage$1,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,076 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$121,177
Medicare patients
478
Services billed
1,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$179,943
TrulicityDulaglutide43$73,980
JardianceEmpagliflozin66$67,395
FarxigaDapagliflozin Propanediol49$49,555
OzempicSemaglutide32$45,878
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$31,619
XareltoRivaroxaban48$26,587
MounjaroTirzepatide16$23,229
Tresiba Flextouch U-200Insulin Degludec29$22,038
Bydureon BciseExenatide Microspheres17$19,376
Breo ElliptaFluticasone/Vilanterol33$16,281
Tresiba Flextouch U-100Insulin Degludec31$15,582
TrintellixVortioxetine Hydrobromide38$14,908
MyrbetriqMirabegron30$9,654
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$179,943327 claims
Lilly USA, LLCTrulicity, Mounjaro$14$97,21059 claims
AstraZenecaFarxiga, Breztri Aerosphere$35$56,98061 claims
Novo NordiskOzempic$64$45,87832 claims
Johnson & JohnsonXarelto$15$26,58748 claims
MerckJanuvia$13$6,33414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →